



Invitation

Stockholm November 2, 2020

Invitation to presentation of Bactiguard's interim report on November 5, 2020

Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday November 5, 2020 at 8:00 CET.

In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on November 5. CEO Cecilia Edström and CFO Gabriella Björknert Caracciolo will present the interim report and answer questions. The report and a presentation for the audiocast will be available at Bactiguard's website www.bactiguard.com

To participate in the audiocast, please use this link:

<https://tv.streamfabriken.com/bactiguard-q3-2020>

To participate only by conference call, dial:

SE: +46850558351 UK: +443333009035 US: +18335268398

Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

For further information, please contact:

Gabriella Björknert Caracciolo, CFO and deputy CEO, mobile: +46 72 141 62 49

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.



Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard at www.bactiguard.com